Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy
Authors:
- Marjo S. van der KnaapMKMarjo S. van der Knaap
- Marianna BugianiMBMarianna Bugiani
- Marisa I. MendesMMMarisa I. Mendes
- Lisa G. RileyLRLisa G. Riley
- Desiree E.C. SmithDSDesiree E.C. Smith
- Joëlle Rudinger-ThirionJRJoëlle Rudinger-Thirion
- Magali FrugierMFMagali Frugier
- Marjolein BreurMBMarjolein Breur
- Joanna CrawfordJCJoanna Crawford
- Judith van GaalenJGJudith van Gaalen
- Meyke SchoutenMSMeyke Schouten
- Marjolaine WillemsMWMarjolaine Willems
- 12 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (11) , e1225-e1237
Abstract
Objective To describe the leukodystrophy caused by pathogenic variants in LARS2 and KARS, encoding mitochondrial leucyl transfer RNA (tRNA) synthase and mitochondrial and cytoplasmic lysyl tRNA synthase, respectively. Methods We composed a group of 5 patients with leukodystrophy, in whom whole-genome or whole-exome sequencing revealed pathogenic variants in LARS2 or KARS. Clinical information, brain MRIs, and postmortem brain autopsy data were collected. We assessed aminoacylation activities of purified mutant recombinant mitochondrial leucyl tRNA synthase and performed aminoacylation assays on patients9 lymphoblasts and fibroblasts. Results Patients had a combination of early-onset deafness and later-onset neurologic deterioration caused by progressive brain white matter abnormalities on MRI. Female patients with LARS2 pathogenic variants had premature ovarian failure. In 2 patients, MRI showed additional signs of early-onset vascular abnormalities. In 2 other patients with LARS2 and KARS pathogenic variants, magnetic resonance spectroscopy revealed elevated white matter lactate, suggesting mitochondrial disease. Pathology in one patient with LARS2 pathogenic variants displayed evidence of primary disease of oligodendrocytes and astrocytes with lack of myelin and deficient astrogliosis. Aminoacylation activities of purified recombinant mutant leucyl tRNA synthase showed a 3-fold loss of catalytic efficiency. Aminoacylation assays on patients9 lymphoblasts and fibroblasts showed about 50% reduction of enzyme activity. Conclusion This study adds LARS2 and KARS pathogenic variants as gene defects that may underlie deafness, ovarian failure, and leukodystrophy with mitochondrial signature. We discuss the specific MRI characteristics shared by leukodystrophies caused by mitochondrial tRNA synthase defects. We propose to add aminoacylation assays as biochemical diagnostic tools for leukodystrophies.Keywords
This publication has 48 references indexed in Scilit:
- Homozygous DMRT2 variant associates with severe rib malformations in a newbornAmerican Journal of Medical Genetics Part A, 2018
- Biallelic mutations in LARS2 can cause Perrault syndrome type 2 with neurologic symptomsAmerican Journal of Medical Genetics Part A, 2017
- Mutations inKARScause early-onset hearing loss and leukoencephalopathy: Potential pathogenic mechanismHuman Mutation, 2017
- Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanismsActa Neuropathologica, 2017
- An Application of NGS for Molecular Investigations in Perrault Syndrome: Study of 14 Families and Review of the LiteratureHuman Mutation, 2016
- Whole exome sequencing in patients with white matter abnormalitiesAnnals of Neurology, 2016
- LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure2015
- Whole exome sequencing of suspected mitochondrial patients in clinical practiceJournal of Inherited Metabolic Disease, 2015
- Aminoacyl‐tRNA synthetases in medicine and diseaseEMBO Molecular Medicine, 2013
- Magnetic Resonance of Myelination and Myelin Disorders2005